Kuwait’s ‘Visionary Lighthouse’ Pavilion Illuminates Expo 2025 Osaka with Innovative Design and a Future-Driven Vision
22.4.2025 16:50:00 CEST | Business Wire | Press release
The Kuwait Pavilion at Expo 2025 Osaka, Kansai, Japan, officially opened its doors today, unveiling a spectacular architectural landmark that embodies the country’s bold vision for the future.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250422295094/en/
The Kuwait Pavilion at Expo 2025 Osaka (Photo: AETOSWire)
Designed as a “Visionary Lighthouse”, the pavilion stands as a dynamic symbol of the ambitious national development plan, New Kuwait 2035, seamlessly integrating the nation’s rich heritage, innovation, and sustainability in a transformative visitor experience that engages audiences from around the world.
Located in the “Empowering Lives” district, the pavilion’s design draws inspiration from Kuwait’s maritime and desert landscapes, reflecting the nation’s journey of resilience, progress, and forward-looking spirit.
Kuwait’s participation in Expo 2025 Osaka highlights the continuation of a long-standing relationship between Kuwait and Japan, built on economic collaboration, cultural exchange, and mutual respect. Having first participated in Expo Osaka in 1970, Kuwait returns 55 years later with a pavilion that emphasises the country’s expanding influence in regional and international development.
Salem Al-Watyan, Commissioner General of the State of Kuwait Pavilion at Expo 2025 Osaka, said: "Our presence at Expo 2025 Osaka is a testament to Kuwait’s enduring friendship with Japan. The pavilion reflects our rich heritage and our commitment to shaping a sustainable and innovative future, highlighting Kuwait’s vision as a leader in global collaboration."
Dr. Naser Al Daihani, Director of the State of Kuwait Pavilion at Expo 2025 Osaka, said: "This pavilion captures Kuwait’s ambition and resilience, offering visitors a unique journey connecting the past and the future. As we celebrate our participation in this global event, we look forward to fostering new partnerships and further enhancing Kuwait’s global presence and influence."
Complementing the architecture, the pavilion’s visual identity draws from the natural elements of Kuwait.
The pavilion’s interactive and immersive interior invites visitors on a multi-sensory journey through Kuwait’s rich past and its bold aspirations for a sustainable, innovative, and technology-driven future. Through storytelling and exhibits, the experience highlights Kuwait’s commitment to empowering lives through progress, knowledge, and collaboration.
The Pavilion's bold, open design blends seamlessly into the public realm while making a strong visual impact.
The pavilion’s inauguration featured the spectacular Pearl Lighting Show, an evocative tribute to Kuwait’s maritime heritage and future aspirations.
The Kuwait Pavilion promises to be one of the most compelling attractions at Expo 2025 Osaka.
Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20250422295094/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom